The dense desmoplastic stroma and insufficient infiltrating T cells limit effective immunotherapy in pancreatic ductal adenocarcinoma (PDAC). The authors here administer an autologous dendritic cell (DC) vaccine (MesoPher) with an agonistic CD40-specific antibody (mitazalimab) to patients with metastatic PDAC after (m)FOLFIRINOX standard-of-care treatment and find MesoPher/mitazalimab combination therapy is safe and tolerable, accompanied with enhanced systemic and local immune responses.
- Songul Kucukcelebi
- Freek R. van ‘t Land
- Casper H. J. van Eijck
